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Considerable research effort has been invested in attempting to understand immune dysregulation leading to
autoimmunity and target organ damage. In systemic lupus erythematosus (SLE), patients can develop a systemic
disease with a number of organs involved. One of the major target organs is the kidney, but patients vary in the
progression of the end-organ targeting of this organ. Some patients develop glomerulonephritis only, while others
develop rapidly progressive end organ failure. In murine models of SLE, renal involvement can also occur. Studies
performed over the past several years have indicated that treatment with LiCl of females, but not males of the
NZB/W model, at an early age during the onset of disease, can prevent development of end-stage renal disease in
a significant percentage of the animals. While on Li treatment, up to 80 % of the females can exhibit long-term
survival with evidence of mild glomerulonephritis which does not progress to renal failure in spite of on-going
autoimmunity. Stopping the treatment led to a reactivation of the disease and renal failure. Li treatment of other
murine models of SLE was less effective and decreased survivorship in male BxSB mice, exhibited little effect on
male MRL-lpr mice, and only modestly improved survivorship in female MRL-lpr mice. This perspective piece
discusses the findings of several related studies which support the concept that protecting target organs such as
the kidney, even in the face of continued immune insults and some inflammation, can lead to prolonged survival
with retention of organ function. Some possible mechanisms for the effectiveness of Li treatment in this context
are also discussed. However, the detailed mechanistic basis for the sex-specific effects of LiCl treatment particularly
in the NZB/W model remains to be elucidated. Elucidating such details may provide important clues for
development of effective treatment for patients with SLE, ~90 % of which are females.
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Background
In autoimmune diseases, immune dysfunction can lead
to the induction of autoantibodies and/or self-reactive
lymphocytes such as T-lymphocytes (reviewed in [1, 2]).
In some autoimmune diseases, such as myasthenia
gravis, the target of the autoantibodies are very specific
for particular tissues (reviewed in [3]), while in others
such as rheumatoid arthritis, several or a few joints can
be involved, but it is a systemic disease. Similarly, in sys-
temic lupus erythematosus (SLE), a spectrum of auto-
antibodies can be present and a number of target tissues
(e.g., kidney, skin, other organs) may be involved (dis-
cussed in [4–6]). As with many autoimmune diseases,
the incidence of such diseases is much greater in females
than males, with the ratio in SLE being ~9 F/1 M
(reviewed in [7]).
With diseases such as SLE, it is clear that there is a
genetic component to the disease (reviewed in [8]), as
well as some ethnic associations (reviewed in [9–12]),
particularly with end-stage renal dysfunction. Thus,
many African-Americans have serious progressive renal
involvement compared to non-African-Americans.
While patients with SLE can have a number of target
tissues involved, the kidney is a major organ that is in-
volved. However, in spite of a somewhat similar pattern of
autoantibodies being present, some patients can have very
modest glomerulonephritis (class I/II) which does not pro-
gress while others can have severe renal involvement
which progresses rapidly to tubulosclerosis and end-stage
renal failure (class III/IV) (discussed in [13, 14]). Details
regarding the basis (e.g., genetics, immunological dysfunc-
tion, target organ responsiveness) for such variation in
renal involvement remain to be elucidated. What is clear
is that in some patients, the target tissue (e.g., kidney) is
somewhat protected from end-stage damage, while in
others, this is not the case. Some of these differences in
human disease appears to have a genetic basis with kid-
ney-associated genes playing a role (reviewed in [15,
16]). While considerable effort has gone into trying to
understand the immune dysfunctions leading to renal in-
volvement with many new treatments (discussed in [14]),
our understanding of target organ resistance to immune
insults is less well defined. However, murine models of
SLE can likely provide useful information regarding hu-
man disease (reviewed in [17, 18]).
Murine models of SLE
There are several mouse models of SLE available for
study (reviewed in [19–21]). Some of these, such as the
MRL-lpr or BxSB mice, have defined mutations that
contribute to the autoimmune disease. For instance, in
the BxSB model, only males get the disease, and in the
MRL-lpr mouse, the parent strain (e.g., MRL-n) has a
number of immune dysfunctions which contribute to
the development of the autoimmunity and includes ex-
cessive lymphoproliferation in the liver and spleen
(reviewed in [19, 20]; and discussed in [22]), factors not
usually observed in patients with SLE. In contrast, in the
NZB/W F1 model both parental strains contribute to
the SLE-like disease, and a number of genes are in-
volved. Some of these relate to the immune dysfunctions
which appear in the F1 mice, while others appear to be
related more to the target organ involvement. In this
NZB/W F1 model, females get a more rapid and pro-
gressive disease with renal failure by ~10–12 months of
age, while the males get a much more mild disease and
do not start to experience overt renal failure until ~20+
months of age (reviewed in [19, 20]). Thus, some sex-
related factors (e.g., sex hormones; discussed in [23, 24])
also appear to play a role in development and progres-
sion of end-stage renal failure, possibly at the level of
sex hormones on immune activities. Therefore, whether
sex hormone variables may be related to immune dys-
function activities or some other factors related to the
kidneys themselves is still not clear, but this point is
relevant to the discussion which follows. Interestingly,
females of the NZB/W F1 combination gain significant
weight as they age, often leading to weights that are
double or more those of the parent strains [25, 26].
Much of this weight is due to subcutaneous and intra-
peritoneal fat deposition. Given parallels between target
organ involvement, and the sex differences noted
above, the NZB/W F1 model was chosen for detailed
investigation regarding treatments that could prevent
renal failure and, thus, prolong the life-span of
animals in the face of immune dysfunction and
autoantibodies.
Influence of lithium chloride treatment on disease
progression in male BxSB, female MRL-lpr, and female
NZB/W mice
Background
Salts of Li have been used extensively in the treatment of
bipolar disease since ~1949 when Cade reported that Li
treatment of guinea pigs led to a calming effect [27]. Inter-
estingly, low concentrations of Li salts are known to be a
component of a number of springs touted as being benefi-
cial for treating a variety of ailments. However, use is often
associated with side effects (reviewed in [28]).
Another limitation of Li salts in the treatment of bipo-
lar disease is that efficacious doses are close to toxic
doses, and thus, patients taking Li salts must be carefully
monitored and evaluated for side effects. As Li salts are
natural compounds, they cannot be patented as such, so
there is little incentive for industry to invest in their ap-
plications. Li exists as two major isotopes, Li-6 and Li-7,
and natural Li is ~95 % Li-7. This is relevant since the
ionic radius of Li-6 is similar to potassium, while that
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for Li-7 is similar to Mg, and thus, the two isotopes
could affect different ionic environments.
Li salts are known to influence adenyl cyclase [29], the
NaK membrane transporter [30], and the Wnt/beta-ca-
tenin system (reviewed in [31]). While it has been very
difficult to identify normal functions of Li in animals, Li
can impact a number of biological systems and thus can
be considered a regulator molecule (discussed in [32]).
In a series of reports in the 1970s, 1980s, and early
1990s, it was demonstrated that Li salts can influence
lymphocyte and polymorphonuclear leukocyte (PMN)
activities both in vitro and in vivo (reviewed in [32–34]).
Therefore, it was possible that Li treatment could have
immunomodulatory influences on immune processes.
While not used in SLE per se, it has been noted that
patients on Li salts who also had SLE sometimes experi-
enced an exacerbation of their SLE, but this was not a
consistent finding (discussed in [32]).
Studies of Li effects on survival in murine models of SLE
Initial studies investigated the effect of 4 mg of LiCl/day
via the intraperitoneal (IP) route on survival of young
male BxSB mice, female MRL-lpr mice, and female
NZB/W mice. Li treatment led to decreased survival in
the BxSB model [35], some modest enhancement of sur-
vival in MRL-lpr female mice, depending on how early
the Li treatment was initiated [22], and significant sur-
vival of female NZB/W mice [25, 26].
In the NZB/W model, survival was significantly pro-
longed by >50 % when the female animals were started on
Li treatment at 8–10 weeks of age, an age when the SLE
was detectable (e.g., autoantibodies in serum, early glom-
erulonephritis) [25, 26]. This enhanced survival in a subset
of female NZB/W mice was a “cure” but was not a defini-
tive cure as stopping Li treatment led to a reactivation of
renal disease and subsequent accelerated death. Therefore,
treatment with Li led to the transient resistance to ter-
minal end-stage renal failure in a subset of female NZB/
W mice with early disease. Why this particular subset of
female animals survived while on treatment, and others
remained susceptible to the autoimmune insults, was un-
clear from these initial studies. However, histologic ana-
lysis of kidneys from some survivors indicated that they
expressed signs of continued glomerulonephritis but ap-
parently failed to convert to tubule sclerosis which is crit-
ical in the development of renal failure. In this regard,
these survivors resembled some human SLE patients who
have evidence for glomerulonephritis class I/II which does
not progress to tubule involvement and sclerosis. Relevant
to the current discussion, female NZB/W mice on Li did
develop polydipsia while being treated, so renal function
was impacted in these mice. Interestingly, polydipsia de-
veloped in all mice treated with Li salts, so this was not
unique to survivors.
Additional studies to further characterize the
effectiveness of LiCl treatment in NZB/W mice
Timing of initiation of treatment
Subsequent studies indicated that there was an age
dependence for the effectiveness of LiCl treatment in
female NZB/W mice. The optimal time to initiate treat-
ment was found to be 6–8 weeks of age, when features
of SLE were just beginning. Delaying initiation of treat-
ment to 16 or 28 weeks of age led to a diminished num-
ber (28–35 %) of long-term survivors [36]. It was also
found that initiating treatment at a very early age of ~4 weeks
of age did not further enhance survival over that observed
at 6–8 weeks of age (~40 % at 4 weeks of age vs 50–60 %
at 6–7 weeks of age) [36]. In fact, starting Li treatment at
4 weeks of age actually led to a somewhat lower long-
term survival rate. Thus, optimization of effectiveness of
LiCl treatment was potentially associated with events oc-
curring between 4 and 6–7 weeks of age, with a ~60 %
long-term survival rate. The most prominent event, with
associated secondary changes occurring in mice during
this time frame, is likely the onset of puberty. Puberty in
mice occurs at ~6 weeks of age (discussed in [37]). As the
cells in the kidneys do express estrogen receptors
(reviewed in [38]), they should be responsive to sex hor-
mones. If this association between the onset of puberty
and optimal LiCl responsiveness is correct, the timing re-
sults likely indicate that Li modulates puberty-associated
changes in gene/protein expression/location in some man-
ner, rather than prevents the expression of some tubule-
associated gene/protein expression.
Effect of isotope, dosage, timing, and route of exposure on
Li effectiveness
Natural Li exists as predominantly two isotopes, Li-7
and Li-6 (discussed in [21, 32–34]). Natural Li is com-
prised of ~95 % Li-7 and ~5 % Li-6. This point is poten-
tially relevant to understanding the mechanism(s) of Li
action as Li-6 has an ionic radius similar to Na, while
Li-7 has an ionic radius more similar to Mg (discussed
in [21, 32–34]). Therefore, Li-6 may affect NaK ATPases
more readily than Li-7. In contrast, Li-7 may affect Mg-
dependent systems more effectively (e.g., adenyl cyclase).
Daily treatment of female NZB/W mice starting at
~8 weeks of age with 4 mg Li-6 (95 %) or Li-7 (99 %)
led to similar survival rates over the long term [25].
Thus, these results did not provide additional insights
into potential mechanistic effects of these Li isotopes.
However, it was noted that Li-6 did induce more poly-
dipsia that did Li-7 (Hart, unpublished observations).
Administration of the LiCl via the drinking water was in-
effective in promoting long-term survival of female NZB/
W mice at doses that were not toxic [39]. Interestingly, Li-6
in the drinking water was much more toxic than Li-7 at the
higher doses investigated [39]. Administration of the Li via
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the IP route was only slightly effective when 2 mg/day was
used instead of 4 mg/day, as assessed by long-term survival
[40]. Interestingly, administering 4 mg LiCl/day via the IP
route was partially dependent on the time of day the Li was
administered, with administration during the morning
more effective than the evening [40]. As mice are more ac-
tive at night, and their adrenal steroid pulses are the reverse
of humans (e.g., higher in the morning and lower in the
afternoon), higher levels of glucocorticoids occur in the
evening. Interestingly, administration of melatonin did not
mimic the effectiveness of Li [40].
Given that administration of 4 mg LiCl in the morning
or evening was effective in protecting a subset of female
NZB/W mice from end-stage renal failure, studies were
undertaken to treat a panel of 6–8-week-old females
with 4 mg LiCl in the morning and evening (a total of
8 mg of Li/day). Animals were treated 7 days/week for
18 months [41]. This treatment regimen led to the long-
term survival of ~80 % of the mice to a time when
100 % of the control mice had been dead for >7 months
[41]. Again, these survivors exhibited some evidence of
glomerulonephritis, but no tubule sclerosis ([41], and
unpublished observations). Furthermore, cessation of Li
treatment at 18 months of age again led to a reactivation
of the disease and subsequent death. Thus, even with
this more intense treatment regimen, one of the major
target organs was only protected during treatment, and
following stoppage of treatment, the target organ was
again apparently susceptible to immune insults. The im-
pact of Li is a reversible phenomenon even after a pro-
tracted treatment protocol. Thus, while on the LiCl
treatment, the vast majority of the NZB/NZW females
were “cured” of the development of end-stage renal fail-
ure, but this cure was conditional and not definitive.
LiCl treatment does not enhance survival of male NZB/W
mice
As discussed above, male NZB/W mice exhibit a more
mild disease course than females (reviewed in [19, 20]).
The onset of the SLE is slower in males, and they live a
much longer life-span. Treatment of male NZB/W mice
with 4 mg LiCl/day IP, 7 days per week starting at 8–
10 weeks of age, did not influence survival out to nearly
81 weeks of age, a time point when ~90 % of the un-
treated controls had died [36]. Therefore, the disease
course must be somewhat different in the females where
the SLE is more aggressive.
The above findings with male NZB/NZW mice, and
the earlier discussion of the effectiveness of LiCl treat-
ment increasing following onset of puberty, lead to the
possibility that androgens are protective against develop-
ment of renal dysfunction and estrogens contribute to
the susceptibility of female NZB/NZW mice to renal
dysfunction. Such conclusions are supported by the
literature, where it has been noted that castration of
male NZB/NZW mice increases their susceptibility to
such renal disease and ovariectomy of female mice leads
to a diminished susceptibility (reviewed in [19, 20]).
Thus, future studies assessing the LiCl responsiveness of
castrated males and ovariectomized females could pro-
vide further clues to the renal mechanisms responsible
for responsiveness. Of particular interest would be com-
parison studies with NZB/NZW mice castrated or ovari-
ectomized prior to onset of puberty or after puberty
onset.
LiCl treatment does not overtly alter autoantibody profiles
in female NZB/W mice
As discussed above, Li ions have been reported to exert
some immunomodulatory effects (discussed in [21, 32–34]).
To investigate whether Li treatment of female NZB/W
mice led to overt immunosuppression, serum from treated
and untreated mice were analyzed for autoantibodies,
antibodies to porcine renal tubule cell lysates [42], and
RNA from treated and untreated mouse kidneys were
assessed for TNF transcripts [43].
To assess the effect of Li treatment on autoantibodies,
female NZB/W mice were started on 4 mg Li-7 at
8 weeks of age. Serum levels for anti-single stranded
DNA and anti-gp70 were not significantly different be-
tween treated and untreated mice at 16, 22, and 28 weeks
of age (prior to renal failure). Western blotting analysis
of serum reactivity to porcine renal tubule lysates from
treated and untreated mice also did not reveal any
group-specific differences, although some individual dif-
ferences were noted within both groups [42]. Similarly,
messenger RNA (mRNA) levels for the proinflammatory
cytokine, TNF-alpha, were similar in extracts of total
kidneys of treated and untreated mice at 28 weeks of age
[43]. While the analysis was not extensive, and did not
evaluate a large number of autoantibodies or cytokines,
no evidence for an overt immune effect of Li treatment
was detected. However, it is clear that technologies have
changed since these studies were performed and the ap-
proach should be revisited to gain a more complete per-
spective regarding Li effects on immune parameters.
Influence of Li treatment on gene expression in the kidney
As mentioned above, mRNA levels for TNF-alpha were
not inhibited by Li treatment in kidneys of Li-treated fe-
male mice. Additional analysis also revealed that expres-
sion of gp70, a reported nephritogenic stimulus [44] in
female NZB/W mice, was not inhibited by Li-treatment
at 16, 22, and 28 weeks of age [43]. In fact, at 22 weeks
of age, mRNA levels for gp70 were significantly elevated
in Li-treated mice.
Interestingly, mRNA levels for the plasminogen activa-
tor, urokinase, were significantly elevated at 16 (p < 0.01),
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22 (p < 0.00001), and 28 (p < 0.01) weeks of age. As uro-
kinase is produced by tubule epithelial cells (reviewed in
[45]), and expression could interfere with fibrin deposition
and development of tubule sclerosis (discussed in [43]),
this finding may be relevant to the mechanism of Li ac-
tion. However, in vivo, it may be more complicated than
that interpretation since elevations in urokinase mRNA
levels were somewhat uniformly elevated in mice at those
ages, but earlier studies had indicated only about 50 % of
the mice would be long-term survivors [25]. Therefore, el-
evated urokinase mRNA levels were associated with Li
treatment, but that association was likely not a complete
explanation for long-term survival in this model.
While not a complete explanation, this finding regard-
ing urokinase is interesting and it may be a contributing
factor in survivorship in these Li-treated mice and assist
in protection against loss of tubule integrity. Urokinase
is produced by convoluted proximal tubule cells and the
thick ascending limb of Henle’s loop [46]. Tubule epithe-
lial cells also express receptors for urokinase, a finding
that may also be relevant for the localization of the uro-
kinase (discussed in [45]). Therefore, there is associated
evidence that urokinase could be involved in long-term
renal protection, but this proteinase cannot explain the
fact that only a subset of Li-treated mice are long-term
survivors as all mice on Li treatment exhibited elevated
urokinase mRNA levels.
As mentioned above, all Li-treated female NZB/W
mice developed polydipsia, and so these associated
changes also do not explain the ~50 % long-term survi-
vors when treated with 4 mg LiCl per day [25]. Interest-
ingly, Rojek et al. [47] have shown in rat models that a
number of renal genes are expressed differently follow-
ing lithium treatment and induction of polydipsia.
Therefore, this approach should likely be repeated with
NZB/W female mice +/− Li treatment to gain further in-
sights in this model. Other investigators have also ad-
vanced the concept that Li is an excellent tool to study
renal physiology and biochemistry (reviewed in [48]).
Interestingly, studies using isolated porcine proximal tu-
bule cells in vitro have indicated they are very resistant to
damage by Li [49]. In contrast, Li treatment of porcine
distal tubule cells in vitro lead to apoptosis of this porcine
cell line (PK (15)) [50]. Thus, different cell populations in
the kidney may be responding to Li exposure in a hetero-
geneous manner. Whether this resistance of porcine prox-
imal tubule cells can be extended to the analogous murine
cells is not known. Unfortunately, in the autoantibody
studies described above (42), we used porcine cell line (PK
(15) and LLC-Pk1) cell lysates but did not use Li-treated
porcine tubule cells for comparison to assess whether Li
treatment led to alterations in detection of specific protein
targets. Such further studies in pig models may lead to
valuable information in this regard.
However, these findings in Li-treated NZB/W mice
could be revisited using improved molecular technologies
to better quantify the molecular and cellular changes oc-
curring and to investigate the potential underlying mecha-
nisms leading to a long-term survivorship while on Li in
more detail. Perhaps, focusing on lithium-mediated effects
on G-protein signaling [51], or molecules such as e-
selectin [52] which contribute to macrophage adhesion
and subsequently, participates in lupus nephritis [53].
Relevant to this discussion is the fact that regulation of e-
selectin expression involves the GSK-3 pathway, a path-
way that can be regulated by LiCl [54, 55].
Possible molecular mechanisms underpinning Li action in
NZB/W female mice
Potential direct effects of Li on the kidney
As mentioned above, Li treatment led to induction of
polydipsia in all mice, and as this is likely due to an ef-
fect on collecting tubule ducts, this is evidence of a dir-
ect impact of Li on these cells. Other in vitro studies
examining the effect of Li salts on porcine renal tubule
cells revealed that Li induced apoptosis in the PK(15)
tubular cell line [50], but the porcine proximal tubule
cell line LLC-PK-2 was very tolerant to similar concen-
trations of Li [49]. While these two cell lines have been
adapted to growth under in vitro conditions, the findings
do potentially indicate that tubule cells derived from dif-
ferent parts of the kidney may respond to Li differently.
At the molecular level, as discussed above, Li can in-
fluence a number of intracellular pathways, and pres-
ently, it is not clear which one(s) are affected by in vivo
treatment of the NZB/W mice. Of particular interest is
the glycogen synthase kinase-3 (GSK-3) pathway which
has become important in a number of systems (reviewed
in [54, 55]) and the Wnt and beta-catenin pathways dis-
cussed earlier. LiCl is known to inhibit renal GSK-3 ac-
tivity in C57Bl/6 mice [55]. Perhaps, with the availability
of a large number of inhibitors for several potential Li
targets becoming commercially available, this could be
revisited to gain more detailed understanding of poten-
tial direct influences of Li on renal cells.
Potential indirect effects of Li
Interestingly, as a consequence of the LiCl treatment of
female NZB/W mice, they failed to gain weight and, spe-
cifically, failed to deposit the usual subcutaneous and
intra-abdominal fat [25, 26]. The lack of fat deposition
was complete and the mice closely maintained their
starting weights. Once treatment was stopped, the sur-
viving mice again started to deposit fat. The basis for
this fat deposition is unknown and its relationship to the
SLE symptoms and disease progression also unknown.
At the time the studies were performed, the observation
was interesting, but how it could be associated with the
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renal function and immune parameters was not overtly
evident. However, it is reported that obesity is associated
with the development of a number of autoimmune dis-
eases [56], so there may also be linkages between pro-
gression of disease via secondary sequelae (e.g., renal
involvement) and obesity.
However, it has been reported that caloric restriction
of female NZB/W mice leads to a decline in cytokine ex-
pression and disease progression irrespective of dietary
fat [57]. More recently, a focus on obesity has revealed
that obesity is associated with development of a meta-
bolic disease, accompanied by a systemic inflammation
(discussed in [58, 59]), as well as the other impacts of
obesity on the kidney [60]. Furthermore, such metabolic
disease may be a risk factor for renal disease (discussed
in [58, 59]). Therefore, it may be necessary to return to
the mechanisms of fat deposition in this model and the
consequences of it as the SLE-like disease progresses, as
it may also be a contributing factor in the disease
process and the renal response to Li. However, Li treat-
ment affected fat deposition in 100 % of the NZB/W
when treatment was started at 8–10 weeks of age, a time
when only ~50 % of the mice were destined to be long-
term survivors. Thus, the fat deposition aspect of the Li
treatment may be only a contributing factor, and sec-
ondary to some as yet, undefined specific target re-
sponse. However, while an impact on diet-related factors
may not account for all of the Li effects on NZB/NZW
female mice, it could be a regulatory component of the
impact which allows or permits some other Li-specific
target(s) to exert a strong impact on survival.
Thus, Li effects on disease progression in NZB/NZW
female mice may relate, in part, to what the animals are
fed or their nutritional status. Mice housed in a univer-
sity vivarium are usually fed a standard chow diet that is
commercially available (most are casein- or corn-based
diets), a diet likely not very similar to what a mouse
would subsist on in the wild. This scenario sets the stage
to ask whether Li treatment was affecting, in as yet un-
identified manners, the impact of this artificial diet on
the immune system, the kidney, an obesity-induced al-
tered inflammatory state, and/or even the mouse micro-
biome [61] of these susceptible NZB/NZW mice.
Relevant to this discussion is a report by Chandrasekar
and Fernandes [62] which indicated that NZB/NZW fe-
male mice fed a diet rich in omega-3 lipids exhibited de-
creased pro-inflammatory cytokine expression, as well as
increased antioxidant gene expression. The treated mice
had an extended life-span, similar to the mice treated
with a single dose of Li/day starting at the age of 8 weeks.
However, in the Chandrasekar and Fernandes studies,
the mice on the omega-3 rich diet weighed the same as
the untreated mice [62]. Therefore, Li treatment could
be impacting the negative influence of the chow diet on
disease development and progression, in part like the
omega-3 rich diet, but with some additional metabolic
targets, possibly mediated by glycogen synthase kinase-3
beta (GSK-3beta; [54, 55]). Interestingly, a number of re-
ports in a variety of murine lupus models [63–67], in-
cluding the MRL-lpr model and the NZB/NZW model
with females, have supported the concept of dietary in-
fluences on disease development and progression, in-
cluding nephritis. Therefore, Li effects on long-term
survival may involve multiple targets due to its range of
metabolic influences.
Of note, it has been reported that obesity is common
in patients with SLE (discussed in [56]). If this possibility
proves to have validity from future investigations, then it
may require stepping back and re-evaluating potential
inductive and exacerbating signals for SLE development
and progression.
Could genetics play a role in the observed protection of
female NZB/W mice with lithium?
In humans, it is clear that the genetics are complex and
likely include contributions from kidney-related genes
[15]. It is also clear that NZB/W mice are an F1 between
the two parental strains (NZB and NZW) and that both
parental strains contribute genes to the F1 SLE pheno-
type (reviewed in [19, 20] and others). Thus, the finding
that ~50 % of the female NZB/W mice were long-term
survivors after initiation of treatment with 4 mg LiCl per
day at 8–10 weeks of age raised the potential interpret-
ation that one half of the mice expressed some genetic
susceptibility from one parent vs the other. However, in-
creasing the dose of LiCl to 2 × 4 mg/day leads to long-
term survival of ~80 % of the mice [41], and therefore,
the higher dose appeared to overcome some limitations
of the 4 mg dose, findings which would tend to temper
the interpretation that long-term survival was associated
with the genetics of one parent vs the other.
To begin to better understand some of the potential
strain-specific effects of LiCl treatment, the response of
a number of commercially available mouse strains (eight
strains from Jackson Laboratories), including the paren-
tal strains (NZB and NZW), to LiCl treatment was
undertaken. The induction of polydipsia in some strains
was induced by lower LiCl concentrations than others
[68, 69], and in some strains, polydipsia was not overtly
induced even by 4 mg LiCl/day. Of particular interest
was the finding that induction of polydipsia in NZB and
C57BL/6 mice occurred at low doses, while higher doses
were required for NZW and BALB/c, and the modest
doses were apparently toxic for A/J mice. The response
of DBA and C3H/HeJ mice was intermediate to that of
the NZB and C57BL/6 mice. What is very interesting
from these data is the fact that the NZB and C57BL/6
mice are black and all of the low/negative responders
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had a white coat color. Furthermore, albino C57BL/6
mice were still responsive to Li induction of polydipsia,
so that the coat color contributions were likely not dir-
ectly involved in polydipsia induction (Hart, unpublished
observations). Interestingly, tyrosine hydroxylase has
also been reported to not be associated with lithium
responsiveness in patients with affective disorders [70].
Furthermore, African-Americans and Hispanics more
responsive to low-dose lithium than are Whites [71].
Therefore, the response patterns to LiCl in mouse
strains may provide some insights to effectiveness in
humans, but it is not yet clear whether there will also be
sex differences in this regard.
Other investigations using very different readouts (e.g.,
brain functioning) have also found somewhat similar re-
sults regarding coat color [72]. In those studies, C57BL/
6 and Black Swiss mice were Li-responders, but CD-1
and NIH Swiss mice (e.g., white coats) were non-
responders to Li treatment. Again, C3H/HeJ mice were
modestly influenced by the Li treatment. Therefore, the
relationship between coat color and lithium effectiveness
is likely a more general phenomenon but could have im-
pacted the responsiveness of the BXSB and MRL-lpr
mice in addition to sex!
The common finding of black coat color being rele-
vant to Li responsiveness is very interesting and may in-
dicate that in the studies detailed with NZB/W F1 mice,
and in spite of the above discussion regarding long-term
survivorship, Li may be primarily influencing genes pro-
vided by the NZB parent, but this speculation remains
to be confirmed.
Interestingly, treatment of female NZB/W F1 mice
with alpha-melanocyte stimulating hormone did not
provide any significant renal protection, so that hormone
is likely not involved in long-term survivorship while on
Li [73]. In contrast, alpha-MSH is reported to ameliorate
SLE-like activity in the pristine-induced mouse model
[74]. Furthermore, alpha-MSH has been reported to
have potent anti-inflammatory activities and protect
against acute renal failure in rodent models, possibly by
direct effects on renal tubules via melanocortin recep-
tors [75]. Therefore, the inability of alpha-MSH to pro-
tect against renal failure in the female NZB/NZW model
is at odds with some of the literature regarding alpha-
MSH and acute renal insults and may be due to the
chronic nature of the SLE-mediated effects or perhaps
due to other non-melanocortin receptor associated
events.
As the genetic basis for mouse coat color and human
pigmentation is very complex [76–81], the relationships
to renal functioning after Li treatment may be very com-
plicated as well, particularly given the sexual dimorph-
ism observed for Li treatment in the NZB/W mice.
However, there may be some “common ground” for
some of the observations related to Li affects on the fe-
males. That is, the melanocortin system may be involved
in coat color, as well as obesity (reviewed in [77, 81])
and the renal system (discussed in [80]). Interestingly,
mutations in the melanocortin-4 receptor are associated
with early onset obesity in humans and in mice [81].
Therefore, it is possible that Li may be affecting ele-
ments of a single, as yet undefined, system to modify the
kidneys of these mice, as well as the loss of fat that was
observed.
Additional considerations regarding why LiCl treatment is
effective in female NZB/W mice
In the NZB/W model, as discussed above, it is known
that subjecting females to ovariectomy leads to an inhib-
ition of disease development and progression (reviewed
in [19, 20]), while castration of males leads to an en-
hancement of the disease progression (reviewed in [19,
20]). However, whether this is due to immune variables
or renal variables cannot be ascertained in detail. Inter-
estingly, the association of Li effectiveness with the onset
of puberty, and the lack of effect in males, may indicate
that the targets of Li treatment are related to either sex
hormone modifications to the kidney or as yet un-
detected immune dysfunction, and the current findings
are consistent with the above information. Interestingly,
the presence of two X chromosomes vs a XY comple-
ment has been reported to impact the onset and pro-
gression of disease on a pristine-induced lupus model
[82]. Furthermore, whether the cells in target tissues ex-
press estrogen receptor alpha or beta (ER-alpha or ER-
beta) may also play a role in gene expression (discussed
in [83–85]) via hormone response elements (complexes
of ER + hormone) or via formation of complexes with
other transcription factors (discussed in [83–85]). Thus,
ER can regulate gene expression alone, as well as in
complexes with hormone. Interestingly, estrogen recep-
tors in NZB/W mice are reported to be variants com-
pared to those in non-SLE mouse strains (reviewed in
[86]). Thus, regulation of gene expression by such vari-
ants may predispose for SLE development and progres-
sion. Therefore, the “how” of Li effects is still not clear
assuming there is a direct link between the kidney and
Li, in addition to other potential targets.
Much of the above discussion has focused on the
“how” LiCl treatment could be influencing female NZB/
W mice, but the real question relates to the “why” be-
hind the observations! The why may also relate to pre-
paring the kidney for pregnancy-related events (e.g.,
mineral retention for a successful pregnancy, specific
cell-type alterations to retain nutrients during pregnancy
to transfer to the offspring, or an increased demand on
general renal function due to carrying large litters (e.g.,
control of hypertension), or other female-specific
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activities related to successful pup survival (e.g., lacta-
tion)). Such speculations must await further investiga-
tion, but such possibilities can be addressed using
modern molecular, biochemical, and genetic tools.
Are the Li treatment of NZB/W female mice findings
relevant to human SLE?
The other important questions of the “why and how” is-
sues relate to extrapolation of the mouse findings to
humans. These are critical questions as considerable
grant funding has gone into understanding these mouse
models, with the hope that the findings are relevant to
the human condition. In humans with SLE, ~90 % of pa-
tients are female, but the incidence of nephritis is higher
in the population of males than in the females [87–90],
but ethnic variables (black, white, Asian) appear to also
play relevant roles in the sexual dimorphism [91–93].
Interestingly, males are often older when the disease is
diagnosed, and some of these men have low sex hor-
mone levels.
Thus, by numbers alone, there are more females with
lupus nephritis than males, but even in the small per-
centage of males, it is common and can be more severe
[9, 86–93]. Therefore, development and progression of
lupus nephritis is either mechanistically different in
males and females, or the findings in NZB/W mice can-
not be readily extrapolated to humans and thus are re-
stricted to mice with a specific background/genetic
makeup (e.g., they are mice after all with millions of
years of optimizing their regulatory systems for survival
of the species). There are however some areas of con-
cordance between murine coat pigmentation with hu-
man skin color, as in human patients with SLE, there
appears to be more renal involvement in non-
Caucasians than Caucasians (discussed in [9, 88, 93]).
Thus, in Caucasians, there may have been some loss of
function associated with skin color during evolution that
did not compromise survival of that subset of humans.
Therefore, whether the “why” of the findings with LiCl
and NZB/W mice can potentially be translated to
humans remains to be determined, but using compara-
tive systems biology approaches, additional commonal-
ities may be elucidated.
Summary
Li treatment has been shown to influence disease course
in murine models of SLE for females, but not males. In
particular, the response of female NZB/W mice to Li is
dramatic from the perspective of survivorship and main-
tenance of renal function. Li treatment has been shown
to alter a number of parameters at the level of the kid-
ney (e.g., prevention of renal sclerosis, induction of uro-
kinase, and induction of polydipsia), but these have not
been directly linked to long-term survivorship while on
Li. Indirect effects of Li (e.g., inhibition of fat deposition)
were also shown but again were not directly linked to
long-term survivorship. While no overt influences of Li
treatment on autoimmunity were detected, the spectrum
assessed in this regard was limited. Therefore, a number
of direct and indirect influences of Li treatment on fe-
male NZB/W mice were detected, but it is not yet
known if and how such changes are related to long-term
survivorship. Long-term survivorship could be dependent
on the constellation of changes observed rather than a sin-
gle alteration, or the constellation of changes could facili-
tate the effectiveness of as yet known effects of the Li to
account for the percentage of female NZB/W mice exhi-
biting long-term survivorship while on Li.
Conclusions
The above discussion has provided evidence that Li
treatment of murine models of SLE yields varied out-
comes. However, the impact on females of the NZB/W
F1 strain is profound, and treatment protects a large
percentage of the treated animals from end-stage renal
failure without detectable impact on immune aberra-
tions. While it is possible that Li treatment did exert
some influences on autoimmunity in the female NZB/W
mice, it is clear that Li treatment modified the impact of
autoimmune dysfunction on the kidney, leading to a
low-grade glomerulonephritis without conversion to
tubulosclerosis and renal failure. This in itself is remark-
able and offers researchers opportunity to pursue the in-
vestigations to elucidate the mechanisms underlying
such target organ resistance. The underlying basis occur-
ring in females and not males is also somewhat remark-
able given the fact that in patients, 90 % are female. At
the genetic level, it is also clear that one likely has to
separate immune dysfunction (e.g., autoimmunity) from
end-organ susceptibility, and the studies presented here
offer a route to explore such differences in detail.
While there are some parallels between the murine
models and patients with SLE (e.g., influence of sex, eth-
nicity, renal involvement, etc.), it is unlikely that Li treat-
ment of patients with SLE will or should occur, and
other aspects of human SLE are different from the mur-
ine models. Firstly, humans likely will not tolerate the
comparable levels of Li required to elicit a response in
the NZB/W mice. The use of Li salts to treat affective
disorders in patients, such as bipolar disease, uses con-
centrations of Li that are close to toxic, and side effects
are common. Secondly, patients on Li usually gain
weight rather than lose it (reviewed in [94]), possibly in-
dicating that the molecular targets in humans may be
somewhat different. Therefore, more detailed study of
the effect of Li on protecting end-organ integrity in the
NZB/W model may provide important clues as to the
molecular basis for the protection, but the tool to
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achieve the goal (e.g., Li) may not be directly translated
to patient populations. However, elaboration of the
mechanisms involved in the NZB/W model may provide
useful information regarding the complexity of the prob-
lem in human populations.
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